PainReform Ltd (NAS:PRFX)
$ 3 -0.37 (-10.98%) Market Cap: 1.77 Mil Enterprise Value: -734,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 27/100

PainReform Ltd at Noble Capital Markets Investor Conference (Virtual) Transcript

Apr 20, 2022 / 04:00PM GMT
Release Date Price: $314.4 (+2.34%)
Ilan Hadar
PainReform Ltd. - CEO

Happy to be here in sunny Florida. First time I'm giving a presentation after a very long time. I'm the CEO of PainReform, a public traded company at NASDAQ. So we do have to go over the forward-looking statements.

And I will present the team. I was lucky to assemble a great group of people helping me managing the company on the day-to-day basis. Some information regarding myself. I was the former Country Manager, and CFO of Foamix Pharmaceuticals before I joined PainReform.

And over there was I [again lucky] to launch successfully two drugs in the US. So the whole team, successful and experienced people with launching drugs in the US and of course, in Israel.

What is PainReform? So the post-operative pain is a growing market, a huge market. Growing market, but there still is an issue because today, as we all know, there is issue with opiates and opioids. Post-operative treatment is really based on giving opioids to the patients, and that leading to dependency.

And there is a need to new kind of drugs that will give post-operation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot